Links to 2 New HCV Treatment Articles from EASL

[Guest guest]

Cyclophilin Inhibitor Alisporivir Active Against HCV in Phase 2b, HBV in Lab

SUMMARY

Cyclophilin inhibitor alisporivir (Debio 025) plus pegylated

interferon/ribavirin boosted sustained response in treatment-naive genotype 1

hepatitis C patients, and also demonstrated antiviral activity against hepatitis

B in a laboratory study, researchers reported at EASL 2011.

TMC435 Beats Standard Therapy Regardless of HCV Genotype

SUMMARY

TMC435 improves response rates of genotype 1 previous non-responder hepatitis C

patients, researchers report at EASL 2011. Further, adding TMC435 helps overcome

the effects of unfavorable IL28B gene pattern and high IP-10 levels.